DOP Session 7

DOP55-63

  • 17:05-18:05 Digital Oral Presentation Session 7: Recent advances of biologic therapies
    Room: C1-M3, Hall C, Bella Center
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
      17:05-17:11 DOP55: ZNF133 is associated with infliximab responsiveness in patients with Inflammatory Bowel Diseases using whole-exome sequencing
    E. S. Jung1,2, K.-w. Choi3, S. W. Kim2, M. Hübenthal1, S. Mucha1, J. Park2, Z. Park3, D. Ellinghaus1, S. Schreiber1, A. Franke1, W. Y. Oh3, J. H. Cheon2
    1
    Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany, 2Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea, 3National Institute of Food and Drug Safety Evaluation, Clinical Research Division, Cheongju, South Korea
      17:11-17:17 DOP56: Dashboard driven versus conventional dosing of infliximab in Inflammatory Bowel Disease patients: The PRECISION trial
    A. Strik1,2, S. Berends3, D. Mould4, R. Mathôt3, C. Ponsioen2, J. van den Brande5, J. Jansen6, D. Hoekman7, J. Brandse8, M. Löwenberg2, G. D'Haens2
    1
    Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Amsterdam UMC, location AMC, Gastroenterology and Hepatology, Amsterdam, Netherlands, 3Amsterdam UMC, location AMC, Hospital Pharmacy, Amsterdam, Netherlands, 4Projections Research Inc., Phoenixville, United States, 5Tergooi Hospital, Blaricum, Netherlands, 6Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 7Amsterdam UMC, location AMC, Clinical Genetics, Amsterdam, Netherlands, 8Amsterdam UMC, location VuMc, Gastroenterology and Hepatology, Amsterdam, Netherlands
      17:17-17:23 DOP57: Monitoring response to anti-TNF therapy in Ulcerative Colitis patients by gastrointestinal ultrasound: Sub-analysis from TRUST&UC
    C. Maaser1, F. Petersen1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, D. Lang4, T. Kucharzik1
    1
    University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany, 2Gastroenterology Practice, Oldenburg, Germany, 3Biostatistik Tuebingen, Tuebingen, Germany, 4AbbVie Deutschland GmbH & Co.KG, Medical Department Gastroenterology, Wiesbaden, Germany
      17:23-17:29 DOP58: IDeaL – a multi-center prospective infliximab dose to level pharmacokinetic study during induction in Paediatric Crohn’s Disease
    G. H. Huynh1, M. W. Carroll1, A. M. Griffiths2, W. El-Matary3, A. Petrova4, C. Prosser5, C. Kluthe6, J. C. deBruyn7, D. Tomalty2, D. R. Mould8, E. Wine4, H. Q. Huynh4
    1University of Alberta, Paediatrics, Edmonton, Canada, 2Hospital for Sick Children, University of Toronto, Paediatrics, Toronto, Canada, 3The Children's Hospital University of Manitoba, Paediatrics, Winnipeg, Canada, 4Stollery Children's Hospital University of Alberta, Paediatrics, Edmonton, Canada, 5Alberta Health Services, Biochemistry, Edmonton, Canada, 6Alberta Health Services, Paediatrics, Edmonton, Canada, 7Alberta Children's Hospital University of Calgary, Paediatrics and Community Health Sciences, Calgary, Canada, 8Projections Research, Phoenixville, United States
      17:29-17:35 DOP59: Proactive infliximab drug monitoring is superior to conventional management in Inflammatory Bowel Disease
    S. Raimundo Fernandes, S. Bernardo, C. Simões, L. Correia, P. Moura Santos, A. Rita Gonçalves, A. Valente, C. Baldaia, R. Tato Marinho
    Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Gastrenterology and Hepatology Unit, Lisbon, Portugal
      17:35-17:41 DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non response in Crohn’s
    P. Pavlidis1, A. Tsakmaki1, U. Niazi2, J. Digby-Bell1, G. Lombardi1, B. Hayee3, G. Bewick1, N. Powell1
    1
    King's College London, London, United Kingdom, 2BRC Bioinformatics core, London, United Kingdom, 3King's College Hospital, London, United Kingdom
      17:41-17:47 DOP61: A nationwide cohort study of colectomy rates for Ulcerative Colitis during the introduction of biologic therapy
    G. Worley1, 2, A. Almoudaris1, 2, P. Bassett3, 4, J. Segal1, 2, A. Akbar2, 4, P. Aylin5, O. Faiz1, 2
    1
    St Mark's Hospital and Academic Institute, Surgical Epidemiology Trials and Outcome Centre, London, United Kingdom, 2Imperial College London, Department of Surgery and Cancer, London, United Kingdom, 3Statsconsultancy Ltd, Buckinghamshire, United Kingdom, 4St Mark's Hospital and Academic Institute, London, United Kingdom, 5Imperial College London, Dr Foster Unit, Department of Primary Care and Public Health, London, United Kingdom
      17:47-17:53 DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomised controlled trial in patients with Active Crohn’s Disease
    W. Reinisch1, B. I. Jang2, V. Borzan3, A. Lahat4, 5, A. Pukitis6, M. Osipenko7, Y. Mostovoy8, S. Schreiber9, S. Ben-Horin10, S. J. Lee11, J. H. Suh11, S. G. Lee11, J. H. Lee11, B. D. Ye12
    1
    Medical University Vienna, Vienna, Austria, 2Yeungnam University Hospital, Daegu, South Korea, 3Clinical Hospital Center Osijek, Osijek, Croatia, 4Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 5Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Pauls Stradins Clinical University Hospital, Rīga, Latvia, 7Novosibirsk State Medical University, Novosibirsk, Russian Federation, 8Private Small_Scale Enterprise Medical Centre "Pulse", Vinnytsya, Ukraine, 9University Hospital Schleswig-Holstein, Kiel, Germany, 10Sheba Medical Center, Tel Hashomer, Israel, 11Celltrion, Inc., Incheon, South Korea, 12Asan Medical Center, Seoul, South Korea
      17:53-17:59 DOP63: Adalimumab for patients with Crohn’s Disease complicated by intra-abdominal abscess: A multi-centre, prospective, observational cohort study
    G. Pineton de Chambrun1, B. Pariente2, P. Seksik3, R. Altwegg1, L. Vuitton4, C. Stefasnescu5, S. Nancey6, A. Aubourg7, M. Serrero8, L. Peyrin-Biroulet9, J. Filippi10, S. Viennot11, V. Abitbol12, M. Boualit13, A. Boureille14, J. Moreau15, A. Buisson16, X. Roblin17, M. Nachury2, M. Zappa18, J. Lambert19, Y. Bouhnik5, GETAID-MICA studygroup1
    1Montpellier University Hospital, Gastroenterology, Montpellier, France, 2Lille University Hospital, Gastroenterology, Lille, France, 3Saint-Antoine University Hospital, Gastroenterology, Paris, France, 4Besançon University Hospital, Gastroenterology, Besançon, France, 5Beaujon University Hospital, Gastroenterology, Clichy, France, 6Lyon University Hospital, Gastroenterology, Lyon, France, 7Tours University Hospital, Gastroenterology, Tours, France, 8Marseille University Hospital, Gastroenterology, Marseille, France, 9Nancy University Hospital, Gastroenterology, Vandoeuvre-les-Nancy, France, 10Nice University Hospital, Gastroenterology, Nice, France, 11Caen University Hospital, Gastroenterology, Caen, France, 12Cochin University Hospital, Gastroenterology, Paris, France, 13Valenciennes General Hospital, Gastroenterology, Valenciennes, France, 14Nantes University Hospital, Gastroenterology, Nantes, France, 15Toulouse University Hospital, Gastroenterology, Toulouse, France, 16Clermont-Ferrand University Hospital, Gastroenterology, Clermont-Ferrand, France, 17Saint-Etienne University Hospital, Gastroenterology, Saint-Etienne, France, 18Beaujon University Hospital, Radiology, Clichy, France, 19Saint-Louis University Hospital, Biostatistics, Paris, France

Digital Oral Presentations
(as of January 2019)

  • DOP Session 1 Advances in IBD pathophysiology
    DOP01-09
    Room: C1 M1
    Chairs: Javier Gisbert, Madrid, Spain
    Maximilian Waldner, Erlangen, Germany
    DOP Session 2 Mechanisms of intestinal inflammation
    DOP10-18
    Room: C1 M0
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    DOP Session 3 Translational science in IBD
    DOP19-27
    Room: C1 M2
    Chairs: Peter Bossuyt, Bonheiden, Belgium
    Axel Dignass, Frankfurt, Germany
    DOP Session 4 Practicalities of IBD patient care
    DOP28-36
    Room: C1 M3
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
    DOP Session 5 Old and new treatment
    DOP37-45
    Room: C1 M4-5
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
  • DOP Session 6 Novel treatments
    DOP46-54
    Room C1 M4-5
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
    DOP Session 7 Recent advances of biologic therapies
    DOP55-63
    Room: C1 M3
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
    DOP Session 8 Intestinal healing
    DOP64-72
    Room: C1 M2
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
    DOP Session 9 Surgery and IBD
    DOP73-81
    Room: C1 M1
    Chairs: Paulo Kotze, Curitiba, Brazil
    Andre D'Hoore, Leuven, Belgium
    DOP Session 10 Clinical epidemiology
    DOP82-90
    Room: C1 M0
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark